Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034

被引：0
|
作者：
Van den Bent, Martin [1 ]
Brandes, Alba
Rampling, Roy [2 ]
Kouwenhoven, Mathilde [3 ]
Kros, Johan M. [4 ]
Carpentier, Antoine [5 ]
Clement, Paul [6 ]
Klughammer, Barbara [7 ]
Bakker, Brenda [8 ]
Lacombe, Denis [9 ]
Gorlia, Thierry [9 ]
机构：
[1] Dr Daniel Den Hoed Canc Ctr, NL-3008 AE Rotterdam, Netherlands
[2] Beatson Oncol Ctr, Glasgow, Lanark, Scotland
[3] EEA, Rotterdam, Netherlands
[4] Erasmus MC, Rotterdam, Netherlands
[5] CHU Pitie Salpetriere, Paris, France
[6] Acad Ziekenhuis, Louvain, Belgium
[7] Hoffmann La Roche AG, Basel, Switzerland
[8] Erasme Univ Hosp, B-1070 Brussels, Belgium
[9] Eortc Data Ctr, Brussels, Belgium
来源：
NEURO-ONCOLOGY | 2007年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：522 / 522
页数：1
相关论文
共 50 条
  • [1] Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034
    Van Den Bent, M. J.
    Brandes, A.
    Rampling, R.
    Kouwenhoven, M.
    Kros, J. M.
    Carpentier, A. F.
    Clement, P.
    Klughammer, B.
    Gorlia, T.
    Lacombe, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): results from a randomized phase II trial (EORTC 26034)
    van den Bent, M. J.
    Brandes, A. A.
    Rampling, R.
    Kouwenhoven, M.
    Kros, J.
    Carpentier, A.
    Clement, P.
    Klughammer, B.
    Lacombe, D.
    Gorlia, T.
    EJC SUPPLEMENTS, 2007, 5 (04): : 228 - 228
  • [3] Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
    van den Bent, Martin J.
    Brandes, Alba A.
    Rampling, Roy
    Kouwenhoven, Mathilde C. M.
    Kros, Johan M.
    Carpentier, Antoine F.
    Clement, Paul M.
    Frenay, Marc
    Campone, Mario
    Baurain, Jean-Francois
    Armand, Jean-Paul
    Taphoorn, Martin J. B.
    Tosoni, Alicia
    Kletzl, Heidemarie
    Klughammer, Barbara
    Lacombe, Denis
    Gorlia, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1268 - 1274
  • [4] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)
    Sathornsumetee, Sith
    Vredenburgh, James
    Rich, Jeremy
    Desjardins, Annick
    Quinn, Jennifer
    Bota, Daniela
    Goli, Krishna
    Mathe, Alyssa
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
  • [5] A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM)
    Brown, P. D.
    Krishnan, S.
    Sarkaria, J.
    Wu, W.
    Mischel, P.
    Yong, W. H.
    Arusell, R.
    Jenkins, R. B.
    Buckner, J. C.
    Giannini, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM)
    Friedman, H. S.
    Desjardins, A.
    Vredenburgh, J. J.
    Rich, J. N.
    Sathornsumetee, S.
    Gururangan, S.
    Quinn, J. A.
    Reardon, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Combination of temozolomide (TMZ) and radiotherapy (RT) versus radiotherapy (RT) alone in newly diagnosed glioblastoma multiforme (GBM): A randomized phase II study
    Athanassiou, H
    Synodinou, M
    Maragoudakis, E
    Paraskevaidis, M
    Verigos, C
    Misailidou, D
    Antonadou, D
    Sarris, G
    Beroukas, K
    Karageorgis, P
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S162 - S163
  • [8] A single-institution phase II trial of radiation (RT), temozolomide (TMZ), erlotinib, and bevacizumab for initial treatment of glioblastoma (GBM)
    Clarke, Jennifer Leigh
    Molinaro, Annette M.
    Butowski, Nicholas A.
    Chang, Susan Marina
    Phillips, Joanna J.
    Costa, Bruno M.
    Costello, Joseph F.
    Rabbitt, Jane E.
    Kivett, Valerie A.
    DeSilva, Ashley A.
    Prados, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] RTOG 0625: A RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB WITH EITHER IRINOTECAN (CPT) OR DOSE-DENSE TEMOZOLOMIDE (TMZ) IN RECURRENT GLIOBLASTOMA (GBM)
    Gilbert, Mark R.
    Wang, Meihua
    Aldape, Kern
    Sorensen, A. Gregory
    Mikkelsen, Tom
    Bokstein, Felix
    Woo, Shaio Y.
    Chmura, Steven J.
    Choucair, Ali K.
    Mehta, Minesh
    NEURO-ONCOLOGY, 2010, 12 : 39 - 39
  • [10] Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
    David M. Peereboom
    Dale R. Shepard
    Manmeet S. Ahluwalia
    Cathy J. Brewer
    Neeraj Agarwal
    Glen H. J. Stevens
    John H. Suh
    Steven A. Toms
    Michael A. Vogelbaum
    Robert J. Weil
    Paul Elson
    Gene H. Barnett
    Journal of Neuro-Oncology, 2010, 98 : 93 - 99
12345